Insider Selling: Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 1,065 Shares of Stock

Tectonic Therapeutic, Inc. (NASDAQ:TECX) insider Marcella Ruddy sold 1,065 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $30.00, for a total value of $31,950.00. Following the sale, the insider directly owned 67,682 shares of the company’s stock, valued at $2,030,460. This represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tectonic Therapeutic Stock Performance

Tectonic Therapeutic stock traded down $0.34 on Wednesday, reaching $29.02. The company’s stock had a trading volume of 215,391 shares, compared to its average volume of 324,762. The business’s fifty day moving average price is $29.24 and its 200 day moving average price is $23.20. The company has a market cap of $546.97 million, a price-to-earnings ratio of -7.17 and a beta of 3.27. Tectonic Therapeutic, Inc. has a twelve month low of $14.39 and a twelve month high of $36.03.

Tectonic Therapeutic (NASDAQ:TECX) last announced its earnings results on Thursday, February 26th. The company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.08. As a group, equities analysts forecast that Tectonic Therapeutic, Inc. will post -4.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tectonic Therapeutic in a research note on Tuesday, April 21st. Truist Financial decreased their price target on shares of Tectonic Therapeutic from $64.00 to $60.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Wall Street Zen downgraded Tectonic Therapeutic from a “sell” rating to a “strong sell” rating in a research note on Saturday, April 18th. Lifesci Capital upgraded Tectonic Therapeutic to a “strong-buy” rating in a report on Thursday, February 5th. Finally, Stifel Nicolaus initiated coverage on Tectonic Therapeutic in a report on Monday, April 13th. They issued a “buy” rating and a $75.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $80.57.

Institutional Investors Weigh In On Tectonic Therapeutic

Several institutional investors and hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its stake in Tectonic Therapeutic by 451.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 3,966 shares of the company’s stock worth $62,000 after buying an additional 3,247 shares in the last quarter. New York State Common Retirement Fund acquired a new position in Tectonic Therapeutic during the 2nd quarter worth approximately $99,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Tectonic Therapeutic in the 2nd quarter valued at $119,000. Los Angeles Capital Management LLC acquired a new stake in shares of Tectonic Therapeutic during the 4th quarter valued at $134,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Tectonic Therapeutic during the 4th quarter valued at $135,000. Institutional investors own 62.63% of the company’s stock.

Tectonic Therapeutic Company Profile

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.